$1.28 Billion in Sales Expected for Hologic, Inc. (NASDAQ:HOLX) This Quarter

Equities analysts predict that Hologic, Inc. (NASDAQ:HOLXGet Rating) will announce $1.28 billion in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Hologic’s earnings. The lowest sales estimate is $1.27 billion and the highest is $1.28 billion. Hologic posted sales of $1.54 billion during the same quarter last year, which would indicate a negative year over year growth rate of 16.9%. The firm is scheduled to report its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Hologic will report full year sales of $4.39 billion for the current year, with estimates ranging from $3.88 billion to $4.55 billion. For the next financial year, analysts anticipate that the company will post sales of $3.94 billion, with estimates ranging from $3.90 billion to $4.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Hologic.

Hologic (NASDAQ:HOLXGet Rating) last released its quarterly earnings results on Wednesday, February 2nd. The medical equipment provider reported $2.17 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.97. Hologic had a net margin of 31.23% and a return on equity of 48.46%. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the firm earned $2.86 earnings per share. Hologic’s revenue for the quarter was down 8.6% compared to the same quarter last year.

A number of research firms recently commented on HOLX. Wells Fargo & Company lowered their price target on shares of Hologic from $95.00 to $90.00 and set an “overweight” rating on the stock in a research report on Thursday, February 3rd. Raymond James lowered their price target on shares of Hologic from $88.00 to $84.00 and set an “outperform” rating on the stock in a research report on Thursday, February 3rd. Morgan Stanley reduced their price objective on shares of Hologic from $76.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 3rd. StockNews.com started coverage on shares of Hologic in a research note on Thursday, March 31st. They set a “buy” rating on the stock. Finally, Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $85.00 to $78.00 in a research note on Wednesday, December 15th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $81.78.

In other news, insider Sean S. Daugherty sold 2,179 shares of the firm’s stock in a transaction that occurred on Thursday, February 24th. The shares were sold at an average price of $71.14, for a total value of $155,014.06. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.54% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Hologic by 2.5% during the 4th quarter. BlackRock Inc. now owns 21,888,278 shares of the medical equipment provider’s stock worth $1,675,766,000 after buying an additional 532,526 shares during the period. State Street Corp boosted its position in Hologic by 3.9% during the 4th quarter. State Street Corp now owns 11,332,073 shares of the medical equipment provider’s stock worth $867,584,000 after buying an additional 423,495 shares during the period. Geode Capital Management LLC raised its holdings in Hologic by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 5,790,351 shares of the medical equipment provider’s stock worth $442,486,000 after purchasing an additional 398,923 shares during the last quarter. Parnassus Investments LLC raised its holdings in Hologic by 0.7% during the 3rd quarter. Parnassus Investments LLC now owns 4,142,799 shares of the medical equipment provider’s stock worth $305,780,000 after purchasing an additional 26,894 shares during the last quarter. Finally, TD Asset Management Inc. raised its holdings in Hologic by 78.9% during the 4th quarter. TD Asset Management Inc. now owns 2,656,184 shares of the medical equipment provider’s stock worth $203,357,000 after purchasing an additional 1,171,229 shares during the last quarter. Institutional investors and hedge funds own 93.12% of the company’s stock.

NASDAQ:HOLX traded up $0.52 during mid-day trading on Friday, reaching $79.99. 1,659,148 shares of the company’s stock were exchanged, compared to its average volume of 1,584,636. Hologic has a one year low of $60.10 and a one year high of $81.04. The firm has a market capitalization of $20.00 billion, a PE ratio of 12.03, a price-to-earnings-growth ratio of 1.23 and a beta of 1.12. The business’s fifty day simple moving average is $73.23 and its two-hundred day simple moving average is $73.02. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.34 and a current ratio of 2.74.

About Hologic (Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Featured Articles

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.